Studies reported that SHP2 is required for the growth of KRAS-mutant non-small-cell lung cancers (NSCLCs), and its inhibition leads to a potential antitumor therapy (Mainardi et al., 2018). This evidence concerns the gene KRAS and non-small cell lung carcinoma.